A New Drug Has Been Created by Altering Dna. What Process Has Been Utilized to Create This Drug?

P T. 2011 Jul; 36(7): 412-416, 419-422, 450.

Pharmacogenomics in Clinical Practice

Reality and Expectations

Introduction

During the by decade, Deoxyribonucleic acid research has advanced from human genome sequencing to the mapping of genetic variations amidst individuals.ⁱ In contempo years, these interindividual genetic variations have been associated with and used to identify potential for disease, drug response, and adverse reactions.¹ Pharmacogenetic enquiry findings accept already been applied to varying degrees in several clinical fields and are expected to support a farther shift toward a more personalized, less empirical approach to health intendance.^two Even so, we are only beginning to sympathise the impact that molecular diagnostics and targeted therapies will have on patient treatment, clinical outcomes, and cost-effectiveness.¹ Despite meaning advances, many scientific, economic, educational, legal, and commercial barriers impede the translation of pharmacogenomic research findings into clinical practice.³

The History of Pharmacogenomics

One of the nearly impressive scientific advances during the past decade was the sequencing of the man genome by the Human Genome Project.ⁱⁱ The complete homo genome sequence was released in April 2003 to coincide with the 50th anniversary of the research publication announcing the discovery of the DNA double helix.^iv Since and so, advances in laboratory technology, calculating, and bioinformatics take allowed genetic inquiry to grow exponentially.⁴ Consequently, genetic research has since shifted from relatively rare monogenic diseases to more mutual and genetically circuitous diseases, such as cancer, cardiovascular and psychiatric disorders, and diabetes.^four These diseases are not only more prevalent; they also affect public wellness to a greater degree, since they are responsible for the majority of disease-related mortality and morbidity.⁴ Genetic research also now explores the office that RNA, proteins, and metabolites play in disease etiology.⁴

Dna sequencing has also been applied to the study of genetically influenced variations in drug response, or "pharmacogenomics." The FDA has divers pharmacogenomics as "the study of variations of DNA and RNA characteristics every bit related to drug response," whereas "pharmacogenetics" is "the written report of variations in DNA sequence as related to drug response."^two More specifically, pharmacogenomics evaluates molecular determinants at the genome-, transcriptome-, and proteome-wide levels, whereas pharmacogenetics involves limited and specific genetic markers.⁵ The awarding of pharmacogenetics to the clinical management of an individual is referred to as "personalized medicine" (PM).ⁱⁱ The goal of PM is to utilize an individual'south genetic data to avert preventable diseases or to choose a handling that has the highest probability of being prophylactic and efficacious according to a person'south genetic makeup.² As is true for almost technologies, the price of DNA sequencing has dropped essentially over the years (Figure i), increasing the likelihood that PM volition go much more prevalent in the futurity.²

An external file that holds a picture, illustration, etc. Object name is f1-PTJ36_7p412.jpg

Cost of sequencing a human-sized genome.

(Modified from the National Man Genome Research Plant, National Institutes of Health, Bethesda, Physician.)

The Promise of Pharmacogenomics

As genomic medicine advances, there is promise that genetic biomarkers will encourage motility abroad from empirical and population-based handling approaches to those that are stratified according to ameliorate patient outcomes, thus ending a "trial-and-error" approach to therapy.^four ^, ⁶ ^– ^viii Information technology is estimated that simply 50% of patients respond positively to their medications.^five ^, ⁹ Therefore, half of the patient population might not exist properly medicated or might experience therapeutic delays if they need to change medications because of a lack of efficacy.^five

Adverse drug reactions (ADRs) are as well unpredictable, even among individuals who are receiving the same therapeutic regimen.⁵ Because ADRs are a leading cause of death in the U.South., this unpredictability represents a significant condom risk.^five Identification of genetic factors that may predispose a patient to an ADR would exist greatly helpful in preventing such reactions.⁵ ^, ⁷ Genetic testing may also exist useful for predicting drug interactions. Estimates reveal that between 20% and 25% of drugs are metabolized, at least in part, past the cytochrome P450 (CYP) isoenzyme 2D6 (CYP2D6).³ Patients with multiple copies of the CYP2D6 gene may therefore exist rapid metabolizers of these drugs and may not accomplish therapeutic plasma levels at the usual drug dose.³ ^, ⁷ Conversely, subjects who take few functional CYP2D6 genes may be deadening metabolizers, causing drug levels to exceed the therapeutic range.³ ^, ⁷

It is also expected that molecular-screening tests volition be able to identify many diseases at before stages, when these atmospheric condition may exist preventable, treatable, or curable.¹⁰ Early DNA testing may become key in affliction-prevention strategies, since genetic data is accessible long earlier many disease processes begin.^two ^, ⁷ For example, detection of an elevated cholesterol level by a laboratory exam may indicate a risk for the future evolution of eye illness.ⁱⁱ However, a genetic analysis might identify a variant in the LDLR gene before cholesterol levels become elevated.² Genetic testing may therefore be more powerful than traditional phenotypic tests, since this Deoxyribonucleic acid mutation tin can exist identified long before cholesterol levels start to rise.²

Genetic testing may also be more than price-effective than phenotypic tests, because delayed diagnosis often leads to increased morbidity and a need for more expensive medical procedures.ⁱⁱ Advanced genomic monitoring assays may likewise provide physicians with an improved ability to detect the likelihood of disease recurrence afterward successful treatment.⁸ ^, ^x In addition, genomic-based prognostic tests might be capable of assessing the adventure of disease progression, and the results, therefore, may be able to inform decisions most whether to apply adjuvant chemotherapy in cancer handling.¹⁰

It has become widely accepted that genetically or molecularly targeted diagnostic tests and therapies are required to further drive the progress in treating many diseases, specially cancer.⁸ ^, ^x Although pharmaceutical companies were initially reluctant to apply pharmacogenomics or biomarkers to drug development, this is now a pervasive strategy.⁸ ^– ¹⁰ Pharmacogenetic testing is used in stage 2A and 2B clinical trials in order to facilitate the development of new molecules and to reduce the associated risks and costs.⁵ ^, ^vii ^, ⁸ In order to develop therapeutics that are targeted toward an private'southward genetic makeup, it is likewise necessary to develop predictive diagnostic genetic tests, known equally "companion diagnostics," along with new drug candidates.⁵ ^, ¹⁰ Companion diagnostics are a critical and necessary complement to targeted drug therapies, since they enable biomarker-stratified patient subsets to be correlated with therapeutic outcomes.^x Pharmacogenetic testing may also benefit pharmaceutical companies by identifying patients who will safely respond to medications that are approved simply aren't often prescribed considering of toxicity and inefficacy issues, potentially expanding market share.^eight

Difficulties Translating Pharmacogenomic Data Into Clinical Practice

Discovery of a biomarker is only the kickoff step in the long and complex process toward its translation into clinical practice.^half-dozen So far, the translation of pharmacogenomic discoveries into clinical practice has been surprisingly disappointing.³ In fact, many genetic biomarkers have non advanced much further beyond identification.^vi This lack of progress may result, in part, from the failure to partially or fully replicate research identifying genetic biomarker associations, an issue that is non uncommon in genetic research.⁶ Overestimation of the magnitude of an outcome can encourage the use of underpowered sample sizes, which often leads to replication failure.⁶ This failure to replicate pharmacogenomic inquiry findings makes information technology hard to establish the clinical validity of a biomarker and can pb to skepticism, confusion, criticism, and ultimately failure to have a examination.⁶

The affect of environmental factors can also complicate the ability to replicate pharmacogenomic inquiry.^iv It has been estimated that only x% to xv% of genetic biomarkers have a straight impact on drug response.³ Instead, drug response phenotypes are more commonly influenced past a circuitous interplay betwixt environmental, genetic, and gene–environment interactions.³ ^, ⁵ For example, it is known that tumor-associated inflammatory responses can down-regulate CYP3A-mediated drug metabolism, thus contributing to drug clearance variability and toxicity of docetaxel (Taxotere, Sanofi-aventis; Docefrez, Sun) in cancer patients.³ In addition, drug interactions can influence drug response and can frequently explicate why a phenotype does not accurately reverberate a genotype for drug metabolism.^three ^, ⁵ Only fragmentary information is known regarding how the interplay between genetics and the surroundings influences pharmacological response.³ These complex factors highlight the demand for prescriptions that are personalized to consider phenotypic, environmental, and genetic data in social club to significantly reduce therapeutic failures and ADRs.^v

Multiple genes can also accept an impact on the predictive value of a genetic biomarker. Historically, many known pharmacogenetic traits were attributed to single nucleotide polymorphisms (SNPs), variations in alleles at a unmarried gene locus that produced clearly discernible phenotypes.³ However, information technology is now thought to exist likely that about drug–response phenotypes outcome from variations at multiple gene loci.³ ^, ⁴ Pharmacogenetic tests that evaluate simply a few genes overlook the contributions of other genetic variations, thereby reducing the predictive value and applications for the exam.^three Pharmacogenetic tests could therefore be more clinically applicable if they included a comprehensive survey of the human genome and considered the multigenic nature of many drug disposition and response phenotypes.³ It is expected that next-generation, whole-genome sequencing will be capable of investigating large genes for diagnostic purposes, a development that has the potential to significantly advance the adoption and clinical utility of pharmacogenomics.² Still, the challenge of identifying the contributions of many variations in multiple genes, and then translating this information into a predictive exam, is formidable.³

A farther complication is the lengthy and all-encompassing investigation that is required to clinically verify genetic risk factors that are suspected of affecting drug pharmacokinetics and pharmacodynamics.^three With only iii% of published clinical information in this field focusing on phase 2 studies and beyond, there is a lack of evidence-based guidelines for many pharmacogenetic applications.⁴ In addition, some biomarker tests are in need of phase three and 4 enquiry to evaluate whether recommended guidelines have been successful in reducing morbidity and bloodshed, such equally testing for HLA-B*5701 and HLA-B*1502 in patients with human being immunodeficiency virus (HIV) or HER2/neu in patients with chest cancer (encounter Table ane, page 419).^four

Table one

List of Selected Clinically Valid Pharmacogenetic Biomarkers and Level of Recommendation For Related Drugs in the Context of FDA-Canonical Drug Labels

Pharmacogenetic Marker^*	Representative Drug	Affliction	Test Name^†
CCR5 expression +++	Maraviroc	HIV infection	Trofile
c-KIT expression +	Imatinib	Gastrointestinal stromal tumor	DakoCytomation c-Kit pharmDx
CYP2C9 variants; VKORC1 variants ++	Warfarin	Thromboembolism	Verigene Warfarin Metabolism Nucleic Acid Test
CYP2C19 variants +	Voriconazole	Fungal infection	Roche Amplichip CYP450 test
CYP2D6 variants +	Atomoxetine, fluoxetine	Attention-deficit hyperactivity disorder, depression, obsessive-compulsive disorders	Roche AmpliChip CYP450 examination
DPD deficiency +	Capecitabine, 5-FU	Colorectal cancer	TheraGuide 5-FU
EGFR expression +	Erlotinib	Non–pocket-sized-jail cell lung cancer	DakoCytomation EGFr pharmDx
EGFR expression and K-RAS mutation +++	Cetuximab, panitumumab	Colorectal cancer	DakoCytomation EGFr pharmDx and Nucleotide sequencing-high-resolution melting (HRM) analysis
G6PDH deficiency +	Primaquine	Malaria	Glucose-6-phosphate dehydrogenase screening
G6PDH deficiency ++	Rasburicase	Hyperuricemia	Glucose-six-phosphate dehydrogenase screening
HER2/NEU overexpression+++	Trastuzumab	Chest cancer	HercepTest
HLA-B^1502* ++ ^‡	Carbamazepine, phenytoin	Epilepsy	HLA typing
HLA-B^5701* ++	Abacavir	HIV infection	HLA typing
NAT variants +	Isoniazid, rifampin	Tuberculosis	Genelex
Ph1 chromosome +	Busulfan	Chronic myelogenous leukemia	BCR/ABL test
Ph1 chromosome +++	Dasatinib, imatinib	Astute lymphoblastic leukemia	BCR/ABL test
PML/RAR gene expression +	Tretinoin	Astute promyelocytic leukemia	PML/RARα quantitative real-time polymerase concatenation reaction
TPMT variants ++	Azathioprine, half dozen-MP, thioguanine	Astute lymphocytic leukemia	Prometheus TPMT Genetics
UGT1A1 variants +	Nilotinib	Chronic myelogenous leukemia	Invader UGT1A1 Molecular Analysis
UGT1A1 variants ++	Irinotecan	Colorectal cancer	Invader UGT1A1 Molecular Analysis

Further investigation is also needed to verify pharmacogenetic testing that is used to decide dose and patient response to warfarin.⁵ Although this practice is somewhat routine and an algorithm even exists for this test, at that place is yet concern regarding its validity and reliability.^four To aid in resolving such issues, the Centers for Illness Control and Prevention (CDC), Office of Public Health Genomics, has sponsored the ACCE Model Projection (analytic validity, clinical validity, clinical utility and associated ethical, legal and social implications [ELSI]) to create a process for evaluating emerging genetic tests.⁶ ^, ¹⁰ ^, ¹¹ The aim of this project was to develop a model organisation for assembling, analyzing, disseminating, and updating existing data on the safety and effectiveness of Dna-based genetic tests and algorithms.¹¹ The procedure includes collecting, evaluating, interpreting, and reporting data on genetic testing in a format that allows policymakers to have access to electric current and reliable information.¹⁰ ^, ¹¹

Some Clinically Significant Pharmacogenetic Findings

Pharmacogenetic testing has been adopted to varying degrees in several clinical fields.ⁱⁱ A word of some of these applications follows.

Oncology

Cancer varies both phenotypically and genetically, even among patients with identical types and stages of disease.^v Many targeted cancer therapies are active against jail cell–surface receptors or downstream effector molecules, and so that mutations in signaling pathway components can influence drug sensitivity and resistance.¹⁰ One major theme emerging from pharmacogenomic enquiry in oncology is that such mutations can inform handling decisions and predict patient outcomes.¹⁰ Significant advances in cancer tissue assay techniques and patient stratification have also occurred in the past decade.^v Much of this progress has been based on the identification of molecular features that determine tumor classification, prognosis, targeted treatments, and treatment response.¹⁰ Diagnostic pharmacogenetic tests for some cancers accept been developed and are now readily available.⁵

The availability of tests for nonheritable, somatic cell Dna mutations is rapidly increasing. The all-time known of these is the HER2 receptor gene amplification examination, which is used to guide breast cancer handling with trastuzumab (Herceptin, Genentech).² ^, ^v HER2 (human epidermal growth factor receptor 2) is overexpressed in approximately ane quarter of patients with breast cancer.⁵ Overexpression of the HER2 oncogene has been establish to correlate with increased tumor formation and metastasis, a poor prognosis, and resistance to chemotherapy.⁵ Trastuzumab treatment is considered only when the patient has HER-positive iii cancer, divers by very high levels of HER2 poly peptide in the tumor.^five Pharmacogenetic testing has become an integral part of the breast cancer handling with trastuzumab, since variability in HER2 receptor gene expression aids in determining degree of patient response.⁵

Pharmacogenomics has also been responsible for significant advances in treating lung cancer. Erlotinib (Tarceva, OSI/Genentech) and gefitinib (Iressa, AstraZeneca) are tyrosine kinase inhibitors (TKIs) designed to target the epidermal growth cistron receptor (EGFR), which has been shown to influence predisposition to lung cancer.⁵ A recent Eastward Asian study investigated the function of an EGFR mutation every bit a predictor for improved progression-costless survival (PFS) with gefitinib treatment compared with carboplatin–paclitaxel therapy.⁵ Results indicated that the response to gefitinib was almost entirely limited to the mutation-positive group, whereas mutation-negative patients benefited more from chemotherapy.⁵ A European written report also screened patients with not–small-cell-lung cancer (NSCLC) for EGFR mutations to place those who were most likely to respond to erlotinib handling.⁵

Two colorectal cancer treatments, cetuximab (Erbitux, Bristol-Myers Squibb/ImClone) and panitumumab (Vectibix, Amgen), are likewise directed confronting the EGFR.^v Mutations in K-ras are idea to actuate the Ras/Raf/MAPK pathway independent of EGF binding and to block the activity of EGFR inhibitors.^v A human relationship between Grand-ras mutations and survival was identified in metastatic colorectal cancer patients treated with cetuximab, showing that the presence of a K-ras mutation was an contained predictor for shorter progression-free and overall survival.⁵ ^, ⁸ A similar relationship between K-ras mutation and lack of response to panitumumab has too been demonstrated.^v In addition to K-ras status, other molecular markers for cetuximab and panitumumab efficacy are beingness investigated.^v For example, increases in EGFR factor copy number have too been shown to correlate with tumor response rate.^five

Cardiology

Pharmacogenomic inquiry in cardiology lagged in the 1990s but has grown chop-chop in recent years.^v In particular, promising discoveries take been made regarding two anti-thrombotic drugs, warfarin(Coumadin, Bristol-Myers Squibb; Jantoven, Upsher-Smith) and clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi-aventis).⁵ Newer anticoagulant agents accept been introduced to the marketplace, such as dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim), which was canonical by the FDA in October 2010.¹² Nevertheless, the oral coumarin anticoagulants (OCAs) warfarin, acenocoumarol, and phenprocoumon accept been the standard treatment for thromboembolic disorders for more than 60 years.⁵ Despite their efficacy, these drugs have a narrow therapeutic window and pose a high hazard of major bleeding, specially during the initial phase of handling.⁵ In that location is also substantial individual variation in response to OCAs, depending on the patient'due south historic period, sex activity, trunk mass index, smoking, vitamin G intake, and concomitant drug therapy, thereby requiring frequent monitoring and dosage adjustment.⁵ Enquiry during the past decade has found that interindividual differences in OCA dose response are also significantly influenced by genetic variations in two enzymes: CYP2C9, which metabolizes OCAs, and VKORC1, the target for these two drugs.⁵ Variations in the CYP2C9*2 and *3 alleles decreased CYP2C9 enzymatic activity and inhibit the metabolism of OCAs, whereas the VKORC1-1639G>A polymorphism influences pharmacodynamic response to coumarins.^five

Discovery of these two polymorphisms caused the FDA to revise the warfarin drug label to include pharmacogenetic information in 2007.^five The revisions indicate that CYP2C9 and VKORC1 genotyping tin can assist in optimizing warfarin dosing and that lower doses may be all-time for patients with the identified genetic variations in one or both of these enzymes.⁵ However, although several pharmacogenetic-based dosing algorithms that incorporate CYP2C9 and VKORC1 genotype data have been proposed for warfarin, medical societies such every bit the American Higher of Breast Physicians have not withal inverse their guidelines because of a lack of sufficient data from prospective randomized studies.⁵ For this reason, large randomized clinical trials are currently planned or nether mode in social club to further determine the influence of pharmacogenetic-guided OCA dosing on treatment outcomes.^v

Clopidogrel is currently the standard of care for acute coronary syndrome;^five it is indicated for patients undergoing percutaneous coronary interventions with or without stenting, the reduction of atherothrombotic events in patients with recent stroke or myocardial infarction, and diagnosed peripheral arterial affliction.^v Nonresponsiveness to clopidogrel is widely reported—approximately 25% of patients taking it experience a subtherapeutic antiplatelet response that is associated with an increased risk of recurrent ischemic events.⁵ Growing show indicates that the response to clopidogrel might exist determined past the CYP2C19 genotype.^five Specifically, the CYP2C19*ii allele impairs CYP2C19 function, which causes a marked decrease in platelet response to clopidogrel.⁵ Consequently, in May 2009, the FDA revised the drug's label to include the bear on of the CYP2C19 genotype on the drug's pharmacodynamics and clinical response.⁵ Recently, a novel allelic variant, CYP2C19*17, was likewise discovered.⁵ Information technology increases the transcriptional activity and enzymatic activeness of CYP2C19, and with an observed prevalence of 30% or less, this variation is quite common in Caucasian populations.⁵

Psychiatry

Recently, several genome-wide clan studies take identified genetic variants that provide new insights into possible molecular targets for antipsychotic and antidepressant agents.^v Typical antipsychotic medications exert furnishings on components of the dopamine pathway.⁵ Published studies have reported a significant clan between polymorphisms in dopamine receptor genes DRD2 and DRD3 and response outcomes.⁵ With respect to atypical antipsychotic agents, pharmacogenetic studies accept reported an association between the serotonin receptor genes HTR2A and HTR2C and response outcomes.^v In addition, depression studies have identified treatment issue associations for genes in the serotonergic and noradrenergic systems.^five Specifically, significant associations have been reported for polymorphisms of the 5-HTTLPR serotonin transporter (SLC6A4) factor as well as for the HTR2A and HTR1A serotonin receptor genes.^five

Genome-wide association studies to identify the genetic determinants of lithium response take likewise been undertaken.^five The phenotypic response to lithium, an ion with antisuicidal and mood-stabilizing effects, is circuitous, and its mechanism of action is unclear.⁵ Nonetheless, many studies take unsaid that genes that encode for components of the inositol pathway may be involved in lithium's mechanism of activity.⁵ Various research papers have also reported associations between lithium response and the five-HTTLPR polymorphism of the SLC6A4 serotonin transporter factor.⁵

Many pharmacogenetic studies in psychiatry have also produced intriguing results regarding genes encoding for stage 1 metabolic enzymes.^five Almost psychiatric drugs are metabolized by CYP 450 isoenzymes.⁵ Specifically, antidepressants and antipsychotic agents are metabolized mainly by the CYP2D6, CYP1A1, CYP3A4, CYP2C9, and CYP2C19 isoenzymes.⁵ A number of studies written report that CYP2D6 polymorphisms predict metabolism and side effects for risperidone (Risperdal, Janssen) simply do not predict response to this psychotropic medication.⁵ Genotyping the CYP2D6 gene may therefore assist health professionals in identifying patients who need to be monitored for risperidone serum levels and ADRs.^five

Although variants in gene encoding for the P450 isoenzyme CYP1A2 have been associated with decreased drug metabolism, these polymorphisms practice not seem to bear upon response to clozapine, a CYP1A2 substrate.⁵ A number of findings have also demonstrated that genetic variants in the gene encoding for CYP2D6 correlate with serum levels of the antidepressants venlafaxine (Effexor, Wyeth/Pfizer), nortriptyline (e.g., Pamelor, Aventyl), and paroxetine (Paxil, GlaxoSmithKline; Pexeva, Noven).⁵ Depressed patients with a duplication of the gene for CYP2D6 have been plant to be ultra-metabolizers of nortriptyline and fail to respond to treatment.^five Conversely, subjects with two nonfunctional copies of the factor for CYP2D6 were shown to exist poor metabolizers of tricyclic antidepressants and had elevated plasma levels of these drugs.^five

Infectious Disease

Pharmacogenomic enquiry has also causeless an important role in infectious disease.^v A genetic biomarker for abacavir (Ziagen, Viiv) hypersensitivity syndrome has been identified and can prevent potentially life-threatening complications from this human immunodeficiency virus (HIV) treatment.² A lower frequency of abacavir sensitivity syndrome had initially been observed in populations with African ancestry, and a higher risk was seen in families, which suggested a genetic component.² Abacavir hypersensitivity syndrome has since been linked to a major histocompatibility complex (MHC) form I allele, HLA B*5701.² ^, ⁵ A pharmacogenetic test is now available to screen Caucasians, the "at-risk" grouping, for this HLA mark.^x

The credence of the HLA-B*5701 allele as a pharmacogenetic marker for abacavir hypersensitivity is ane of the few examples of the rapid evolution of a genetic biomarker from research tool to clinical utilise.¹⁰ This evolution was driven by stiff clinical utility and alignment of stakeholder interests.^ten One study reported that screening for the HLA-B5701 allele has reduced abacavir hypersensitivity syndrome reactions to less than 1%, compared with four% to 8% before HLA testing was routinely performed.⁵

The c.516G/T variant in the CYP2B6 gene has also been identified as a potential pharmacogenetic marker for ADRs in patients who have been treated with efavirenz (Sustiva, Bristol-Myers Squibb).⁶ Furthermore, nucleotide substitutions in genes encoding for the organic anion transporter i, or multidrug-resistant protein ii or iv, have been associated with an increased risk of kidney tubulopathy in patients receiving tenofovir disoproxil fumarate (Viread, Gilead), a nucleotide analogue used in HIV therapy.^five Certain polymorphisms, such as the c.3435C/T variation in the MDR1 gene, can also exist used to predict antiretroviral therapy response.⁵

The therapeutic direction of infectious diseases has been challenged by antibiotic resistance, which is mainly a consequence of improper prescribing and utilize of antimicrobials.⁵ Personalized medicine (PM) for infectious diseases is a developing concept in which molecular biology tools are used to provide more rapid, informative, and accurate diagnostic assays, enabling more effective treatment.⁵ Over the by decade, several companies accept adult various nucleic acrid testing assays for the direct detection of viral pathogens and some resistant bacteria in clinical samples.^v These new technologies offer faster diagnosis and will probable slowly replace classical phenotypic methods of identifying and determining antimicrobial susceptibility patterns for microbes.⁵ These novel, rapid molecular diagnostic tools will provide clinicians with real-time, crucial clinical information that should profoundly improve the management of microbial and viral infections.⁵

Some Currently Available Pharmacogenetic Tests

A number of pharmacogenetic tests are commercially bachelor or are existence performed in selected laboratories.^five A scattering of these poly peptide- and Dna-based tests have been canonical by the FDA for in vitro diagnostic testing.⁵ Early tests tended to place a single genetic mutation to predict a patient'south take chances for disease; nevertheless, newer tests tin can evaluate thousands of genes and dozens of genetic variations.¹³

One of the first test kits available was HercepTest (Dako), which was approved in 2001 by the Center for Devices and Radiological Health (CDRH) for detecting the overexpression of HER2 poly peptide in breast cancer tissue.⁵ ^, ⁷ Similar tests that measure HER2 gene copy number using fluorescence in situ hybridization (FISH) are also available.⁵ Complex multigene products for breast cancer diagnosis are also now emerging, such equally the FDA-canonical, 70-gene-based MammaPrint (Agendia).² This test is designed to stratify patients with early-stage chest cancer into low- and high-risk groups to assist in long-term management decisions.^two

In 2005, the FDA approved the AmpliChip CYP450 Exam (Roche Molecular Systems), the kickoff pharmacogenetic test for genotyping 27 CYP2D6 and three CYP2C19 alleles that are associated with different drug-metabolizing phenotypes.⁵ The test is used to predict the metabolic rate for drugs that are substrates of CYP isoenzymes 2D6 and 2C19.^v ^, ^seven Another test, the DMET Plus Panel (Affymetrix), covers an fifty-fifty wider range of genetic variations that influence drug metabolism, including mutual and rare SNPs, insertions, deletions, trialleles, and copy number variants, many of which are not assayed past conventional pharmacogenetic methods.^five The DMET Plus Panel identifies 1,936 drug metabolism biomarkers present in 225 genes, including all of those that the FDA has included in drug labels.⁵ The panel tin place common genetic variants with allelic frequencies of approximately 20%, along with assimilation, distribution, metabolism, and excretion (ADME) markers that have allelic frequencies beneath ix%.⁵

Pharmacogenetic tests that place predictors of ADR susceptibilities to antipsychotic pharmacotherapies have also been adult.⁵ The PhyzioType (Genomas) system employs 384 SNPs from 222 genes as well equally a biostatistical algorithm.⁵ Genomas is waiting for a patent and FDA approval for this test.⁵ The PGxPredict:clozapine test (PGxHealth) detects a nucleotide polymorphism in the HLA-DQB1 gene.⁵ This exam predicts the likelihood of clozapine-induced agranulocytosis and helps to decide hazard–benefit balance for clozapine handling.^five Laboratory tests that detect genetic factors that may influence psychotropic pharmacodynamics (such as genetic variants in the HTR2A, HT2RC, and 5-HTT genes that predict clozapine response) can also now be performed.⁵

Other pharmacogenetic tests that can detect the HLA-B*1502 allele for carbamazepine (e.chiliad., Carbatrol, Tegretol, Epitol)–induced Stevens–Johnson syndrome, are beingness performed in some laboratories.⁵ This test is recommended by the FDA for patients of Asian descent, based on the finding that the incidence of this reaction is x times higher in this population.⁵ ^, ^ix Some boosted pharmacogenetic tests are presented in Table i.³

Obstacles to the Translation Of Pharmacogenomics Into Clinical Practice

Many pregnant scientific, economic, educational, legal, and commercial barriers impede the translation of pharmacogenomics into clinical practice (Effigy 2, page 420).³ ^, ⁹ These are discussed next.

An external file that holds a picture, illustration, etc. Object name is f2-PTJ36_7p412.jpg

Influences on drug-response phenotype and obstacles impeding personalized medicine.

(Modified from Squassina A. Pharmacogenomics 2010;11[8]:1149–1167. With permission of the Time to come Scientific discipline Group.⁵)

Lack of Comparative- and Cost-Effectiveness Data

Prove that the cost of pharmacogenetic testing is justified past clinical outcome is lacking and needs to exist generated, ideally through comparative effectiveness research.^v ^, ⁹ Unfortunately, although the number of published reports regarding the cost-effectiveness of pharmacogenetic biomarkers has been increasing, the data are withal scarce and often inadequate, incomplete, or contradictory, or neglect to demonstrate cost savings.⁶ Because of rising constraints on health intendance expenditures, it is essential that pharmacogenomic studies, particularly randomized controlled trials, be designed to include a thorough cost-effectiveness analysis.⁶ Such an assay is likely to demonstrate that pharmacogenetic testing leads to improved clinical care but is cost-effective just for certain genetic marker tests, diseases, and treatments.^five ^, ⁸ Those who design cost-effectiveness studies must also consider the expense for the computational resources, storage, and interpretation that will be required to procedure, analyze, and relieve the generated genetic data.² ^, ¹⁴

Demand for Education and Clinical Do Guidelines

Educational programs and guidelines for the utilization of pharmacogenetic data in clinical decision-making also need to be adult and disseminated.¹⁴ Medical professionals have best-selling that they lack the training to utilise pharmacogenetics in clinical do.¹⁵ A 2008 survey (sponsored by the American Medical Association and Medco Health Solutions) of more than than x,000 physicians found that 98% of respondents were enlightened that a patient's genetic profile could influence response to drug therapy.¹⁵ Even so, only ten% of the surveyed physicians felt that they were adequately informed to apply pharmacogenetic data to clinical decision-making.¹⁵ Furthermore, only 26% of survey takers reported that they had received pharmacogenomic preparation during medical school or postgraduate grooming.¹⁵ Predictably, physicians who considered themselves to be well informed were twice equally likely to order pharmacogenetic tests.¹⁵

Studies besides testify that patients expect wellness intendance professionals to competently explain and interpret pharmacogenetic test results.⁵ Governmental regulations that may prohibit direct-to-consumer access to genetic tests are reasonable simply if wellness intendance providers are fairly trained to counsel patients.¹⁶ In an effort to correct this noesis gap, the International Gild of Pharmacogenomics has requested that deans of educational activity at medical schools include pharmacogenomic training in the core medical curriculum.⁵ This request was fabricated in order to prevent dr. education from creating a bottleneck in the implementation of PM.^five

The lack of clinical practice guidelines and algorithms is an additional bulwark to the translation of pharmacogenetics into clinical practice.² ^, ^{half dozen} ^, ^nine Guidelines need to be robust, up to appointment, and consistent but also flexible then that they can be quickly revised to reflect new inquiry findings.¹¹ In gild to facilitate developments in this field, regulatory agencies such as the FDA and the European Medicines Agency have published guidance documents.^six ^, ¹⁷ Clinical guidelines define simply best medical practices and are often insufficient to change clinical practice.⁶ Therefore, multipronged approaches may be essential, such every bit regulatory changes that are coordinated with changes to clinical guidelines.⁶

Reimbursement Policies

Payer reimbursement policies exert a great influence on the improvidence of pharmacogenetic tests into clinical exercise.^five Currently, diagnostic tests in the U.S. are reimbursed co-ordinate to Current Procedural Terminology (CPT) codes and Medicare clinical laboratory-fee and physician-fee schedules.^ten All the same, different models have been proposed to pay for pharmacogenomic testing, including value-based pricing, pay-for-operation, or even "coin-back guarantees."¹

Experts accept suggested that changes in the Centers for Medicare and Medicaid Services (CMS) reimbursement policies for pharmacogenetic tests are critical to the more widespread improvidence of this applied science into clinical exercise.⁵ However, such changes are not likely to occur soon.⁵ Although the FDA revised the warfarin label to include information well-nigh the influence of the CYP2C9 and VKORC1 genes in 2007,^v the CMS has approved Medicare reimbursement for pharmacogenetic warfarin tests but when they are performed during a prospective randomized controlled study that meets certain criteria.⁵ The CMS policy is based on regulations that state "tests for screening purposes ... performed in the absence of signs, symptoms, complaints, or personal history of disease or injury are not covered, except equally explicitly authorized by statute."⁵

Insurers take been reluctant to reimburse for expensive diagnostics and therapeutics because they don't have data demonstrating that disease prevention is cost-effective.^viii ^, ⁹ It has therefore been predicted that equitable payer reimbursement volition occur only when public and individual insurers acknowledge that targeted patient therapies tin can produce toll savings.⁸ ^, ^ten However, some contempo positive insurer reimbursement decisions regarding targeted therapies take been based on a pay-for-performance model that considered clinical and cost-effectiveness information and thereby recognized the economical value of molecular diagnostics.¹⁰ Nevertheless, some studies take shown that toll-effectiveness analyses don't e'er influence reimbursement.^seven Instead, the two almost important factors influencing reimbursement identified were the strength of clinical evidence and endorsement by professional guidelines.¹⁰ However, the disparity between the cost of randomized clinical trials needed to clinically validate pharmacogenetic tests and the traditionally low rates of reimbursement for diagnostics poses challenges.¹⁰ This disparity can potentially threaten the motivation of exam developers, manufacturers, and laboratories to develop or offering pharmacogenetic tests.¹¹

Regulatory Issues

By including pharmacogenetic information in an increasing number of drug labels, the FDA has been one of the main proponents of PM.⁶ However, the regulation of pharmacogenetic tests and targeted therapies by ii separate centers within the FDA is an impediment.^ane The Center for Drug Evaluation and Inquiry (CDER) regulates targeted therapies, whereas the Center for Devices and Radiological Health (CDRH) regulates molecular diagnostics.¹ The FDA has agreed that the regulatory oversight of pharmacogenetic tests needs to be re-examined and that clear guidance on new biomarkers is forthcoming.^ane ^, ⁹ In a 2010 address, FDA Commissioner Margaret Hamburg identified three areas for improving the regulatory oversight of pharmacogenetics: (i) the need for a more flexible regulatory path and production blessing process that adapts to genomic and clinical data; (ii) collaboration between government regulatory and research agencies; and (3) transparency between the regime, industry, and patient communities to maximize the condom and efficacy of genetic diagnostics and therapeutics.^nine

A more constructive regulatory arrangement volition also be necessary to navigate the complex issues surrounding patient and kin protection with respect to genetic data buying, a discussion that has already been initiated.^xiv Although historically, commercial test kits have mostly been the focus of FDA oversight, the agency has initiated a public dialogue regarding the development of a consistent, reasonable, and fair approach to all genetic tests, including those performed in a laboratory.¹³

Quality Control

In order for molecular diagnostics to exist successfully implemented, guidelines that emphasize best practices with respect to technical functioning, belittling validation, clinical interpretation, and proficiency need to be established.^nine ^, ¹⁰ Yet, establishing quality balls and proficiency guidelines at a stride that matches biomarker discovery and development is a significant challenge.¹⁰ In fact, the electric current lack of standards for loftier-quality specimens and assays has become one of the nigh meaning barriers to progress in cancer research.¹⁰

Ideally, diagnostic providers should collaborate with the medical customs and global proficiency testing organizations (Quality Control for Molecular Diagnostics, Uk National External Quality Cess Service, and NordiQC) to ensure that interpretation training and proficiency-testing programs for molecular diagnostics are in place.¹⁰ Pathologists volition as well exist expected to include molecular diagnostic results in surgical pathology reports and therefore should also establish quality-command processes that ensure efficacy and accuracy.^ten

Delivery

Information technology has been shown that point-of-care testing profoundly improves clinical decision-making and outcomes.² Ideally, pharmacogenetic tests will also exist performed on a point-of-care basis, enabling wellness practitioners to make on-the-spot decisions regarding drug option and dose.² One current obstacle to performing point-of-intendance pharmacogenetic testing is the need for polymerase chain reaction (PCR) analysis.^two However, it is predicted that this obstacle may exist overcome as alternatives to Dna amplification are developed.² For case, development of third-generation DNA sequencers that can analyze single molecules, therefore circumventing the demand for cloning or distension, is now being discussed.²

Pharmacogenetic discoveries also need to be adapted into diagnostic technologies that are analytically accurate, reproducible, reliable, price-effective, and compatible with sample types that are obtainable in routine clinical practice.¹⁰ ^, ^fourteen Molecular technologies must as well deliver diagnostic reports inside a clinically useful turnaround time.¹⁴ Further, pharmacogenetic tests performed in large academic laboratories often use nonstandardized assays.¹⁰ This is an additional reason that pharmacogenetic testing needs to progress to a point where it is standardized and can be applied within a routine clinical setting.¹⁰

Privacy

Because pharmacogenetic testing identifies an individual'south disease risk, it inspires questions regarding privacy, genetic discrimination, and eligibility for health insurance or employment.^five ^, ⁹ The fact that data sharing is considered essential to pharmacogenomic research further complicates this issue.^iv To illustrate, a typical question on an informed consent course for a pharmacogenomics study might request permission to shop a participant's genetic data and material along with phenotypic data.⁴ Permission to access an individual'south electronic patient record might also be requested in order to acquire future phenotypic data.⁴ Although genetic research soon occurs inside a academy medical center or a research establish, collaboration among enquiry groups also makes information technology likely that genetic samples, information, or both, will exist sent elsewhere.^four The samples or data might besides be used to investigate traits that the participant doesn't know about, since they were non defined in the original research written report clarification.^four

The level of genetic sample confidentiality in pharmacogenomic studies ranges from bearding to identified.^iv Although unidentified samples are the most individual, researchers may discourage this option, because unidentified information are considerably less valuable with respect to verifiability and follow-up.⁴ In improver, few collected samples are truly anonymous.⁴ Rapid advances in applied science go far possible to generate, shop, and share highly specific participant-unique information.⁴ This increases the likelihood that "bearding" genetic information could exist linked to a particular person.⁴ Ironically, this was illustrated when the genome of Dr. James Watson, a discoverer of the Deoxyribonucleic acid double helix, was sequenced.^iv He agreed to release his genetic information to public databases except for information regarding apolipoprotein Due east (Apo E), a protein associated with late-onset Alzheimer's disease.^iv However, fifty-fifty with this information excluded, Dr. Watson's genotype could exist imputed with more than that 99% certainty considering of linkage disequilibrium betwixt polymorphisms flanking Apo East.⁴

In 2008, in order to encourage U.S. citizens to participate in genetic research and testing, Congress passed the Genetic Information Nondiscrimination Act (GINA),⁴ ^, ⁹ which provides citizens with protection against the misuse of genetic information past employers and insurers.⁹ Specifically, GINA prohibits insurers from using genetic information to decide underwriting decisions and employers from using these data to make selections regarding who gets hired, fired, or promoted.^nine This legislation also prevents health insurers from requesting applicants to submit to genetic testing before they are granted coverage.^ix All the same, some experts argue that because employers are yet permitted to request admission to health records of potential employees or their medical examination findings, the value of GINA is mainly symbolic.⁴ Other areas in which GINA is said to fall short include the fact that this legislation protects simply individuals with a genetic predisposition and not a diagnosed disease, and it doesn't prohibit long-term-care and life insurers from using genetic information to select plan participants.⁹

Sources of Impetus

Although many barriers currently interfere with the translation of pharmacogenomics into clinical practice, in that location are also some sources of impetus. A brief discussion regarding several of these influences follows.

Pharmacoeconomics

Apace increasing medical costs go on to outpace our projected ability to pay for health care.² This trend has encouraged a greater focus on preventive medicine.² Molecular diagnostics holds great hope for the prevention of disease, even in "low resources" settings.^four It likely volition besides be price-effective for practicing physicians to employ pharmacogenetic tests to optimize treatment selection and prevent ADRs.³ For example, a lack of therapeutic efficacy can be as plush every bit drug toxicity, so it would be economically advantageous to place treatment responders prior to therapy.³

Although we are only starting to proceeds an understanding of how pharmacogenetic-guided therapy can touch on costs and clinical outcomes, it seems highly likely that pharmacogenetic testing will reduce health care expenditures.ⁱⁱⁱ Pharmacy benefit managers Medco and CVS Caremark have besides advocated existent-world pharmacogenetic comparative-effectiveness studies.¹ ^, ^viii These companies have a combined fellow member base of operations totaling more than 100 million Americans.¹ With such an enormous public achieve, they are well positioned to promote this research and to make pharmacogenetic testing bachelor to a big population.^ane

Drug Label Revisions

To date, the FDA has approved more than than 200 drug labels that include information regarding genetic biomarkers; this number has increased substantially over the past decade.^three However, in many cases, the drug labels provide this content for informational purposes only (see Table i, page 419).^three Few labels recommend or require that biomarker testing be performed before a therapeutic conclusion is made.^three ^, ⁹

Despite this trend, the inclusion of pharmacogenetic information in drug labels past the FDA has still had a positive impact. For example, the FDA revision of the drug labels for warfarin and clopidogrel triggered additional inquiry that will likely lead to further pharmacogenetic insights.¹ The increasing inclusion of pharmacogenetic information in drug labels has also caused a surge in the number of pharmacogenetic tests available.³

Nonprofit Advocacy Groups

During the by few years, nonprofit foundations have also undertaken initiatives to promote the clinical implementation of PM.^five The Personalized Medicine Coalition is such an organisation; it is composed of many pharmaceutical, biotechnology, diagnostic, and it companies; wellness care providers and payers; patient advocacy groups; industry policy organizations; academic institutions; and government agencies.^v This arrangement encourages the clinical use of molecular diagnostics and PM; provides opinion leadership and public educational activity; and disseminates data to the media, authorities officials, and health care leaders.^five

Conclusion

Pharmacogenomics is redefining how illness is diagnosed, classified, and treated. Pharmacogenetic testing is at present essential to the development and clinical use of many molecular diagnostics and targeted therapies. Even so, the many scientific, economic, educational, legal, and commercial barriers that be need to be overcome earlier the full potential of pharmacogenetics and PM is achieved.⁹ Awareness of, and attending to, these diverse challenges are essential in gild to let pharmacogenetic technologies to provide innovative clinical treatments and optimize patient outcomes. Continued research, too as the participation of all involved stakeholders, will be necessary to overcome these formidable barriers.⁹

References

1. Freuh Felix W. Real-world clinical effectiveness, regulatory transparency, and payer coverage: Three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics. 2010;xi(v):657–660. [PubMed] [Google Scholar]

2. Trent RJ. Pathology practice and pharmacogenomics. Pharmacogenomics. 2010;11(1):105–111. [PubMed] [Google Scholar]

3. Gervasini 1000, Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol. 2010;66(viii):755–774. [PubMed] [Google Scholar]

four. Vijverberg SJ, Pieters T, Cornel MC. Ethical and social issues in pharmacogenomics testing. Curr Pharm Des. 2010;16(2):245–252. [PubMed] [Google Scholar]

5. Squassina A, Manchia M, Manolopoulos VG, et al. Realities and expectations of pharmacogenomics and personalized medicine: Impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010;xi(8):1149–1167. [PubMed] [Google Scholar]

half-dozen. Pirmohamed One thousand. Acceptance of biomarker-based tests for awarding in clinical exercise: Criteria and obstacles. Clin Pharmacol Ther. 2010;88(6):862–866. (online, October 27, 2010). [PubMed] [Google Scholar]

7. Vogenberg FR, Barash CI, Pursel Thou. Personalized medicine, office 1: Evolution and development into theranostics. P&T. 2010;35(10):560–576. [PMC gratuitous article] [PubMed] [Google Scholar]

8. Vogenberg FR, Barash CI, Pursel M. Personalized medicine, part 3: Challenges facing wellness care plans in implementing coverage policies for pharmacogenomic and genetic testing. P&T. 2010;35(12):670–675. [PMC free article] [PubMed] [Google Scholar]

nine. Vogenberg FR, Barash CI, Pursel Thou. Personalized medicine, function 2: Ethical, legal, and regulatory issues. P&T. 2010;35(eleven):624–642. [PMC free article] [PubMed] [Google Scholar]

ten. Walk EE. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare. Curr Opin Drug Discov Dev. 2010;thirteen(2):226–234. [PubMed] [Google Scholar]

xi. Centers for Disease Control and Prevention (CDC) Genetic testing: ACCE model system for drove, analyzing, and disseminating information on genetic tests. Available at: world wide web.cdc.gov/genomics/gtesting/ACCE/FBR/alphabetize.htm. Accessed May 6, 2011. [Google Scholar]

xiv. Taylor BS, Ladanyi 1000. Clinical cancer genomics: How soon is now? J Pathol. 2011;223(2):318–326. [PubMed] [Google Scholar]

15. Prainsack B, Wolinsky H. Direct-to-consumer genome testing: Opportunities for pharmacogenomics enquiry. Pharmacogenomics. 2010;eleven(5):651–655. [PubMed] [Google Scholar]

xvi. Ries NM, Castle D. Nutrigenomics and ethics interface: Direct-to-consumer services and commercial aspects. OMICS J Integr Biol. 2008;12(4):245–250. [PubMed] [Google Scholar]

Articles from Chemist's shop and Therapeutics are provided here courtesy of MediMedia, USA

broussardfixied73.blogspot.com

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171815/